Banque Pictet & Cie SA lowered its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 4.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 60,994 shares of the company’s stock after selling 2,651 shares during the period. Banque Pictet & Cie SA’s holdings in Teva Pharmaceutical Industries were worth $950,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in TEVA. Bruderman Asset Management LLC increased its stake in Teva Pharmaceutical Industries by 2,175.0% in the fourth quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after acquiring an additional 2,262 shares during the last quarter. Lindbrook Capital LLC increased its stake in Teva Pharmaceutical Industries by 61.2% in the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after acquiring an additional 945 shares during the last quarter. Cullen Frost Bankers Inc. bought a new position in Teva Pharmaceutical Industries in the first quarter valued at $40,000. Rational Advisors LLC bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $49,000. Finally, Capital Investment Advisory Services LLC bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $56,000. 67.01% of the stock is currently owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries stock opened at $14.60 on Thursday. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66. The stock has a market cap of $14.65 billion, a PE ratio of 5.21, a PEG ratio of 2.91 and a beta of 1.30. Teva Pharmaceutical Industries Ltd has a 1-year low of $14.04 and a 1-year high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.02. The company had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. Teva Pharmaceutical Industries’s revenue for the quarter was down 15.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.94 earnings per share. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd will post 2.3 earnings per share for the current year.
A number of research analysts have recently issued reports on the company. UBS Group raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Wednesday, January 23rd. Raymond James raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 price objective on the stock in a research note on Thursday, February 14th. Piper Jaffray Companies raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $15.00 to $16.00 in a research note on Wednesday, January 23rd. Bank of America reaffirmed a “buy” rating and set a $24.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, February 5th. Finally, Zacks Investment Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Monday, January 21st. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $20.58.
In other news, insider Deborah A. Griffin sold 4,107 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $69,326.16. Following the completion of the sale, the insider now directly owns 2,941 shares in the company, valued at $49,644.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Notaristefani Carlo De sold 5,041 shares of the stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $17.88, for a total transaction of $90,133.08. Following the sale, the vice president now owns 17,162 shares of the company’s stock, valued at $306,856.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,691 shares of company stock valued at $283,458. 0.49% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Ltd (TEVA) Shares Sold by Banque Pictet & Cie SA” was originally posted by Equities Focus and is the sole property of of Equities Focus. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.equitiesfocus.com/2019/05/09/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-banque-pictet-cie-sa.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: Roth IRA
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.